Navigation Links
Cell Therapeutics Reports Second Quarter 2013 Financial Results
Date:7/31/2013

ent of its clinical trials; that CTI cannot predict or guarantee the outcome of preclinical and clinical studies; that CTI may not obtain reimbursement for PIXUVRI in certain markets in the E.U. as planned or at all; that the conditional marketing authorization for PIXUVRI may not be renewed or may be subject to additional conditions; that the second Phase 3 clinical trial of pacritinib will not occur as planned or at all; that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities; that CTI may experience delays in the commencement of preclinical and clinical studies; risks related to the costs of developing, producing and selling PIXUVRI, pacritinib, and CTI's other product candidates; and other risks, including, without limitation, competitive factors, technological developments, costs of developing, producing and selling PIXUVRI, that CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI's average net operating burn rate may increase, that CTI will continue to need to raise capital to fund its operating expenses, but may not be able to raise sufficient amounts to fund its continued operation, as well as other risks listed or described from time to time in CTI's most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K.  Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

PIXUVRI is a registered trademark of Cell Therapeutics, Inc.

Contacts:Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
ebell@ctiseattle.com

In EuropeCTI Life Sciences Limited, Milan Branch
Laura Villa
+39 02 89659706

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , August 27, 2014 ... Equipment Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental ... published by MarketsandMarkets, the global Dental Equipment Market is ... $5,416.3 million in 2014, growing at a CAGR ... Browse 95 market data tables and 61 figures ...
(Date:8/27/2014)... , Aug. 27, 2014 Pulse Systems, ... (EHR) , Practice Management , and Revenue Cycle ... known business practices performed by some RCM vendors, at UBM ... PA on September 19-20, 2014.  ... will return in September with a new session encouraging practices ...
(Date:8/27/2014)... HONG KONG , Aug. 27, 2014 /PRNewswire/ ... ("Sihuan Pharmaceutical" or the "Company"), a leading pharmaceutical ... franchise in China,s prescription ... of the Company and its subsidiaries (collectively the ... 2014 (the "Period"). Financial HighlightsFor the ...
Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 4Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... (Nasdaq: STXS ) announced today financial results for ... with the preliminary results reported on October 13, 2010. Third ... and reductions in both operating loss and net loss. ... compared to $13.3 million in the third quarter 2009. As ...
... Quality Forum (NQF) announces the election of leadership ... NQF is a unique, multi-stakeholder, nonprofit ... healthcare by setting national priorities and goals for ... and publicly reporting on performance, and promoting the ...
Cached Medicine Technology:Stereotaxis Reports Third Quarter Financial Results 2Stereotaxis Reports Third Quarter Financial Results 3Stereotaxis Reports Third Quarter Financial Results 4Stereotaxis Reports Third Quarter Financial Results 5Stereotaxis Reports Third Quarter Financial Results 6Stereotaxis Reports Third Quarter Financial Results 7National Quality Forum Members Elect New Council Leaders 2
(Date:8/27/2014)... Aug. 26, 2014 (HealthDay News) -- Health care workers ... gear to keep them safe from being infected with ... study shows. While the study was conducted before ... spring, its findings are confirmed in statistics released Monday ... health agency reported that an "unprecedented" number of health ...
(Date:8/27/2014)... and a new UCLA study has shown this is definitely ... decisions about how to treat their prostate cancer. , UCLA ... disease have a much more difficult time making treatment decisions, ... quality of their care and their long-term outcomes. , The ... can use the findings to target men less likely to ...
(Date:8/27/2014)... CIC microGUNE, the Co-operative Research Centre into ... seeks to generate innovative solutions based on ... mobility industry and life sciences, among others. ... Tecnun are collaborating with CIC microGUNE on ... funded by the Etortek 2013-2014 programme of ...
(Date:8/27/2014)... a week of tomatoes have an 18 per cent ... , With 35,000 new cases every year in the ... second most common cancer in men worldwide. , Rates ... is linked to a Westernised diet and lifestyle. , ... risk of prostate cancer, researchers at the Universities of ...
(Date:8/27/2014)... news release is available in German . ... for medical agents to treat metastatic tumors. In case of ... that is often detected late, 95% of the patients die ... develops tumor therapeutic agents that might reduce this mortality rate. ... now received a total of EUR 5 million from investors. ...
Breaking Medicine News(10 mins):Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 2Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 3Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Preclinical development of tumor therapeutic agent starts 2
... VP of Products and Marketing Will Address Growing Healthcare Trends ... Tools ... Michael Flanagan, VP of products,and marketing for Portico Systems, the ... Optimizing Provider,Network Management" at the Institute for International Research,s,conference in ...
... Barcelona, Spain: Recent political decisions have had serious ... at ECCO 14, the European Cancer Conference, today ... the Federation of European Cancer Societies (FECS) said ... take an active role in engaging with policymakers ...
... spontaneous quit attempts can be successful, PITTSBURGH, ... quit attempt may not be the path to ... for a quit attempt, a new national,survey conducted ... quitting may not require an advance plan.(1) In ...
... of Diabetic Neuropathy Market Will Be Driven by Launches, of ... ... Resources, WALTHAM, Mass., Sept. ... firms for pharmaceutical and,healthcare issues, finds that by 2016 Genentech/Roche,s Lucentis ...
... the Cure with its ... Emmy Award-winning journalist and TV personality Cristina ... Munchkin, Inc. -- maker of award-winning infant and ... again reminding women everywhere "Don,t Duck a ...
... to encourage an individual to get screened for ... according to researchers at Jefferson Medical College in ... interventions that guide recipients through the screening process ... primary care practices. , Ronald Myers, Ph.D., professor ...
Cached Medicine News:Health News:Portico Systems to Share Provider Network Management Best Practices at Institute for International Research 2Health News:Political decisions harming cancer treatment in Europe 2Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 2Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 3Health News:Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning 4Health News:Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets 2Health News:Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research 2Health News:Jefferson researchers find personalized interventions key to improving colon cancer screening rates 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: